LabCorp Steps into NGS-based Oncology Market as Foundation Medicine Adds Hematologic Cancer Test | GenomeWeb

Laboratory Corporation of America entered the next-generation sequencing oncology market this week with the launch of a 50-gene cancer panel for tumor analysis, while Foundation Medicine expanded its testing menu by releasing a 405-gene panel for hematologic cancers last week.

LabCorp's IntelliGen assay covers approximately 2,600 mutations in 50 oncogenes or tumor suppressor genes and will be available through Integrated Oncology, one of the firm's specialized laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.